Refractory Acute Lymphoblastic Leukemia (ALL)
Oncology·MeSH: Leukemia, Myeloid, Acute
Prevalence
8.0 / 100K
Incidence
1.8 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| kte-c19 | Kite Pharma, Inc. (KITE) |
Frequently asked questions
How many drugs are in development for Refractory Acute Lymphoblastic Leukemia (ALL)?
BioSniper tracks 1 drug in development for Refractory Acute Lymphoblastic Leukemia (ALL) across 1 company.
How many clinical trials target Refractory Acute Lymphoblastic Leukemia (ALL)?
There are 2 clinical trials targeting Refractory Acute Lymphoblastic Leukemia (ALL) tracked by BioSniper.
What is the prevalence of Refractory Acute Lymphoblastic Leukemia (ALL)?
The estimated prevalence of Refractory Acute Lymphoblastic Leukemia (ALL) is approximately 8.0 per 100,000 population.
Deep-dive into Refractory Acute Lymphoblastic Leukemia (ALL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis